EBMT 2023 | Using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in B-ALL
Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, comments on the benefits of reducing or substituting chemotherapy with bispecific antibodies before allogeneic transplantation in children with B-cell precursor acute lymphoblastic leukemia (B-ALL), explaining that immunotherapy is less toxic than chemotherapy and allows patients to achieve a deep remission prior to transplantation. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Medac: Honoraria; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Riemser: Consultancy, Speakers Bureau; Jazz: Other, Research Funding; Neovii: Research Funding.
